Up to date in sexually transmitted infections: Epidemiology, diagnostic approaches and treatments;Actualización en infecciones de transmisión sexual: Epidemiología, diagnóstico y tratamiento

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 7, 2004, Pages 392-411

  Vázquez, Fernando ^a,e   Otero, Luis ^b   Ordás, José ^c   Junquera, María Luisa ^a   Varela, José Antonio ^d  

^a HOSPITAL MONTE NARANCO   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d Unidad de ITS   (Spain)

^e UNIVERSIDAD DE OVIEDO   (Spain)

Author keywords

Diagnosis; Epidemiology; Sexually transmitted infections; Treatment

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BORIC ACID; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIDOFOVIR; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; EVERNIMICIN; FAMCICLOVIR; GATIFLOXACIN; GLYCYLGLYCINE; INTERFERON; LEVOFLOXACIN; LINEZOLID; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; UNINDEXED DRUG; VALACICLOVIR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENOME; BACTERIUM CULTURE; CALYMMATOBACTERIUM GRANULOMATIS; CHLAMYDIA TRACHOMATIS; CONDYLOMA; FEMALE; GENE SEQUENCE; GENITAL HERPES; GONORRHEA; HERPES; HUMAN; MYCOPLASMA GENITALIUM; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; REVIEW; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TREPONEMA PALLIDUM; VAGINA CANDIDIASIS; VIRUS TRANSMISSION;

EID: 4844225498     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13065527     Document Type: Review

References (297)

1. García Pérez A, Del Río de la Torre E. Los orígenes de la enseñanza de la Dermatología en España. Actas Dermosifilogr 1997;88:421-33.
2. Castejón Bolea R. La aparición de la Dermatología y Venereologia como disciplina médica en España. Rev Intern Dermatol & Dermocosm Clin 2000;3:444-9.
3. Gerbase AC, Rowley JT, Heymann DHL, Berkley SF, Piot P. Global prevalence and incidence estimates of selected curable STDs. Sex Trans Infect 1998;(Suppl 1):512-6.
4. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002;51(No. RR-6).
5. Radcliffe KW. Introduction. European STD guidelines. Int J STD AIDS 2001;12(Suppl 3):2-3.
6. Van Voorst Vader PC, Radcliffe KW. European guideline for the organization of a consultation for sexually transmitted diseases. Int J STD AIDS 2001;12(Suppl 3):4-6.
7. Thorvaldsen J. European guideline for testing for HIV infection. Int J STD AIDS 2001;12(Suppl 3):7-13.
8. Goh BT, Van Voorst Vader PC. European guideline for the management of syphilis. Int J STD AIDS 2001;12(Suppl 3):14-26.
9. Bignell CJ. European guideline for the management of gonorrhoea. Int J STD AIDS 2001;12(Suppl 3):27-9.
10. Stary A. European guideline for the management of chlamydial infection. Int J STD AIDS 2001;12(Suppl 3):30-3.
11. Patel R, Barton SE, Brown D, Cowan FM, Kinghorn GR, Munday PE, et al. European guideline for the management of genital herpes. Int J STD AIDS 2001;12(Suppl 3):34-9.
12. Von Krogh G, Lacey CM, Gross G, Barrasso R, Schneider A. European guideline for the management of anogenital warts. Int J STD AIDS 2001;12(Suppl 3):40-7.
13. Brook MG. European guideline for the management of hepatitis B and C virus infections. Int J STD AIDS 2001;12(Suppl 3):48-57.
14. Scott GR. European guideline for the management of scabies. Int J STD AIDS 2001;12(Suppl 3):58-61.
15. Scott GR. European guideline for the management of pediculosis pubis. Int J STD AIDS 2001;12(Suppl 3):62.
16. Horner PJ. European guideline for the management of urethritis. Int J STD AIDS 2001;12(Suppl 3):63-7.
17. Edwards SK. European guideline for the management of balanoposthitis. Int J STD AIDS 2001;12(Suppl 3):68-72.
18. Sherrard J. European guideline for the management of vaginal discharge. Int J STD AIDS 2001;12(Suppl 3):73-7.
19. Roest RW, Van der Meijden WI. European guideline for the management of tropical genito-ulcerative diseases. Int J STD AIDS 2001;12(Suppl 3):78-83.
20. Ross JD. European guideline for the management of pelvic inflammatory disease and perihepatitis. Int J STD AIDS 2001;12(Suppl 3):84-7.
21. Horner PJ. European guideline for the management of epididymo-orchitis and syndromic management of acute scrotal swelling. Int J STD AIDS 2001;12(Suppl 3):88-93.
22. Carlin EM, Keat AC. European guideline for the management of sexually acquired reactive arthritis. Int J STD AIDS 2001;12(Suppl 3):94-102.
23. Fraser CM, Norris SJ, Weinstock GM, White O, Sutton GG, Dodson R, et al. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 1998;281:375-88.
24. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998;282:754-9.
25. Hobbs MM, Leonardi MJ, Zaretzky FR, Wang TH, Kawula TH. Organization of the Haemophilus ducreyi 35000 chromosome. Microbiology 1996;142:2587-94.
26. Glass JI, Lefkowitz EJ, Glass JS, Heiner CR, Chen EY, Cassell GH. The complete sequence of the mucosal pathogen Ureaplasma urealyticum. Nature 2000;407:757-62.
27. Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, Fleischmann RD, et al. The minimal gene complement of Mycoplasma genitalium. Science 1995;270:397-403.
28. Black CM, Morse SA. The use of molecular techniques for the diagnosis and epidemiologic study of sexually transmitted infections. Curr Infect Dis Reports 2000;2:31-43.
29. Centers for Disease Control and Prevention. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections-2000. MMWR Morb Mortal Wkly Rep 2002;51(RR-15):1-40.
30. Grimes DA, Schiltz KF. Uses and abuses of screening tests. Lancet 2002;359:881-4.
31. Zenilman JM, Miller WC, Gaydos C, Rogers SM, Tuner F. LCR testing for gonorrhea and chlamydia in populations surveys and other screenings of low prevalence populations: coping with decreased positive predictive value. Sex Transm Infect 2003;79:94-7.
32. Katz AR, Effler PV, Ohye RG, Brouillet B, Lee MV, Whiticar PM. False-positive gonorrhea test results with a nucleic acid amplification test: The impact of low prevalence on positive predictive value. Clin Infect Dis 2004;38:814-9.
33. WHO/Global Program on AIDS. Global prevalence and incidence of selected curable sexually transmitted diseases: overview and estimates. WHO/GPA/STD 1995;1:1-26.
34. Varela JA, Otero L, García MJ, Palacio V, Carreño F, Cuesta M, et al. Trends in the prevalence of pathogens causing urethritis in Asturias, Spain, 1989-2000. Sex Transm Dis 2003;30:280-3.
35. Otero L, García Ma. J, Varela JA, Palacio V, Vázquez F. Prevalencia de Chlamydia trachomatis en población de riesgo de Asturias [carta]. Enf Infecc Microbiol Clin 2002;20:368-9.
36. Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med 2003;349:2424-30.
37. Morse SA, Ballard RC, Holmes KK, Moreland AA, editors. Atlas of sexually transmitted diseases and AIDS (third edition). Edinburg: Mosby, 2003; p. 379.
38. Cosentino LA, Landers DV, Hillier SL. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by strand displacement amplification and relevance of the amplification control for use with vaginal swab specimens. J Clin Microbiol 2003;41:3592-6.
39. Schachter J, McCormack WM, Chernesky MA, Martin DH, Van Der Pol B, Rice PA, et al. Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis. J Clin Microbiol 2003;41:3784-9.
40. Moncada J, Chow JM, Schachter J. Volume effect on sensitivity of nucleic acid amplification tests for detection of Chlamydia trachomatis in urine specimens from females. J Clin Microbiol 2003;41:4842-3.
41. Shafer MA, Moncada J, Boyer CB, Betsinger K, Flinn SD, Schachter J. Comparing first-void urine specimens, self-collected vaginal swabs, and endocervical specimens to detect Chlamydia trachomatis and Neisseria gonorrhoeae by a nucleic acid amplification test. J Clin Microbiol 2003;41:4395-9.
42. Goessens WH, Mouton JW, Van der Meijden WI, Deelen S, Van Rijsoort-Vos TH, Lemmens-den Toom N, et al. Comparison ot three commercially available amplification assays, AMP CT LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol 1997;35:2628-33.
43. Steingrimsson O, Jonsdottir K, Olafsson JH, Karlsson SM, Palsdottir R, Davidsson S. Comparison of Roche Cobas Amplicor and Abbott LCx for the rapid detection of Chlamydia trachomatis in specimens from high-risk patients. Sex Transm Dis 1998;25:44-8.
44. Chernesky MA, Chong S, Jang D, Luinstra K, Sellors J, Mahony JB. Ability of commercial ligase chain reaction and PCR assays to diagnose Chlamydia trachomatis infection in men by testing first-void urine. J Clin Microbiol 1997;35:982-4.
45. Davis JD, Riley PK, Peters CW, Rand KH. A comparison of ligase chain reaction to polymerase chain reaction in the detection of Chlamydia trachomatis endocervical infections. Infect Dis Obstet Gynecol 1998;6:57-60.
46. Pasternack R, Vuorinen P, Pitkajarvi T, Koskela M, Miettinen A. Comparison of manual Amplicor PCR, Cobas Amplicor PCR, and LCx assays for detection of Chlamydia trachomatis infection in women by using urine specimens. J Clin Microbiol 1997;35:402-5.
47. Puolakkainen M, Hiltunen-Back E, Reunala T, Suhonen S, Lahteenmaki P, Lehtinen M, et al. Comparison of performances of two commercially available tests, a PCR assay and ligase chain reaction test, in detection of urogenital Chlamydia trachomatis infection. J Clin Microbiol 1998;36:1489-93.
48. Stary A, Schuh E, Kerschbaumer M, Gotz B, Lee H. Performance of transcription-mediated amplification and ligase chain reaction assays for detection of chlamydial infection in urogenital samples obtained by invasive and non-invasive methods. J Clin Microbiol 1998;36:2666-70.
49. Hook EW 3rd, Smith K, Mullen C, Stephens J, Rinehardt L, Pate MS, et al. Diagnosis of genitourinary Chlamydia trachomatis infections by using the ligase chain reaction on patient-obtained vaginal swabs. J Clin Microbiol 1997;35:2133-5.
50. Polaneczky M, Quigley C, Pollock L, Dulko D, Witkin SS. Use of self-collected vaginal specimens for detection of Chlamydia trachomatis infection. Obstet Gynecol 1998;91:375-8.
51. Thomas BJ, Pierpoint T, Taylor-Robinson D, Renton AM. Sensitivity of the ligase chain reaction assay for detection Chlamydia trachomatis in vaginal swabs from women who are infected at other sites. Sex Transm Dis 1998;74:140-1.
52. Ostergaard L, Andersen B, Olesen F, Moller JK. Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study. Br Med J 1998;317:26-7.
53. Kacena KA, Quinn SB, Howell MR, Madico GE, Quinn TC, Gaydos CA. Pooling urine simples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J Clin Microbiol 1998;36:481-5.
54. Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex Tranm Infect 1998;74:66-70.
55. Dean D, Millman K. Molecular and mutation trends analyses of omp1 alleles for serovar E of Chlamydia trachomatis: implications for the immunopathgenesis of disease. J Clin Invest 1997;99:475-83.
56. Stohard DR, Bogulawaski G, Jones RB. Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pahtogenic determinants. Infect Immun 1998;66:3618-25.
57. Suchland RJ, Eckert LO, Hawes SE, Stamm WE. Longitudinal assessment of infecting serovars of Chlamydia trachomatis in Seattle public health clinics: 1988-1996. Sex Transm Dis 2003;30:357-61.
58. Jonsdottir K, Kristjansson M, Hjaltalin Olafsson J, Steingrimsson O. The molecular epidemiology of genital Chlamydia trachomatis in the greater Reykjavik area, Iceland. Sex Transm Dis 2003;30:249-56.
59. Geisler WM, Suchland RJ, Whittington WL, Stamm WE. The relationship of serovar to clinical manifestations of urogenital Chlamydia trachomatis infection. Sex Transm Dis 2003;30:160-5.
60. Bowden FJ, Tabrizi SN, Garland SM, Fairley CK. Infectious diseases. 6: Sexually transmitted infections: new diagnostic approaches and treatments. Med J Aust 2002;176:551-7.
61. Martin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med 1992;327:921-5.
62. Brocklehurst P, Rooney G. Interventions for treating genital Chlamydia trachomatis infection in pregnancy. Cochrane Database Syst Rev 2000;(2): CD000054.
63. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001;184:1352-4.
64. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol 2001;9:197-202.
65. Fennema JS, Cairo I, Coutinho RA. Substantial increase in gonorrhoea and syphilis among clients of Amsterdam Sexually Transmitted Diseases Clinics. Ned Tijdschr Geneeskd 2000;144:602-3.
66. Centers for Disease Control. Control of Neisseria gonorrhoeae infection in the United States: report of an external consultants' meeting convened by the Division of STD Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 10-11 October 2001. Disponible en: http://www.cdc.gov/std/GCmtgreport.pdf
67. US Prevention Services Task Force. Guide to clinical services. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality, 1996:293-302. Disponible en: http://www.ahrq.gov/clinic/cpsix.htm.
68. Alary M, Baganizi E, Guedeme A, Padonou F, Davo N, Adjovi C, et al. Evaluation of clinical algorithms for the diagnosis of gonococcal and chlamydial infections among men with urethral discharge or dysuria and women with vaginal discharge in Benin. Sex Transm Infect. 1998;74 Suppl 1:S44-9. (Erratum en: Sex Transm Infect 1998;74:459.
69. Alary M, Baganizi E, Guedeme A, Padonou F, Davo N, Adjovi C, et al. Evaluation of clinical algorithms for the diagnosis of gonococcal and chlamydial infections among men with urethral discharge or dysuria and women with vaginal discharge in Benin. Sex Transm Infect. 1998;74 Suppl 1:S44-9. (Erratum en: Sex Transm Infect 1998;74:459.
70. Farell DJ. Evaluation of AMPLICOR Neisseria gonorrhoeae PCR using cppB nested PCR and 16S rRNA PCR. J Clin Microbiol 1999;37:386-90.
71. Ostergaard L, Agner T, Krarup E, Johansen UB, Weismann K, Gutschik E. PCR for detection of Chlamydia trachomatis in endocervical, urethral, rectal, and pharyngeal swab samples obtained from patients attending an STD clinic. Genitourinary Med 1997;73:493-7.
72. Debattista J, Clementson C, Mason D, Dwyer J, Argent S, Woodward C, et al. Screening for Neisseria gonorrhoeae and Chlamydia trachomatis at entertainment venues among men who have sex with men. Sex Transm Dis 2002;29:216-21.
73. Page-Shafer K, Graves A, Kent C, Balls JE, Zapitz VM, Klausner JD. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men. Clin Infect Dis 2002;34:173-6.
74. Tabrizi SN, Paterson BA, Fairley CK, Bowden FJ, Garland SM. Comparison of tampon and urine as self-administered methods of specimen collection in the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women. Int J STD AIDS 1998;9:347-9.
75. Kacena KA, Quinn SB, Hartman SC, Quinn TC, Gaydos CA. Pooling of urine simples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J Clin Microbiol 1998;36:3624-8.
76. Billings SD, Fuller D, LeMonte AM, Davis TE, Hartstein AI. Characterization of DNA-negative, probe-positive Neisseria gonorrhoeae by pulsed field gel electrophoresis. Diagn Microbiol Infect Dis 1997;29:281-3.
77. Cooke SJ, De la Paz H, La Poh C, Ison CA, Heckels JE. Variation within serovars of Neisseria gonorrhoeae detected by structural analysis of outer-membrane protein PIB and by pulsed-field gel electrophoresis. Microbiol 1997;143:1415-22.
78. Harnett N, Brown S, Riley G, Terro R, Krishnan C, Pauze M, et al. Analysis of Neisseria gonorrhoeae in Ontario, Canada, with decreased susceptibility to quinolones by pulsed-field gel electrophoresis, auxotyping, serotyping and plasmid content. J Med Microbiol 1997;46:383-90.
79. Hobbs MM, Alcorn TM, Davis RH, Fischer W, Thomas JC, Martin I, et al. Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community. J Infect Dis 1999;179:371-81.
80. Poh CL, Ramachandran V, Tapsall JW. Genetic diversity of Neisseria gonorrhoeae IB-2 and IB-6 isolates revealed by whole-cell repetitive element sequence-based PCR. J Clin Microbiol 1996;34:292-5.
81. Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis 1997;3:33-9.
82. Newman LM, Wang SA, Ohye RG, O'Connor N, Lee MV, Weinstock HS. The epidemiology of fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii, 2001. Clin Infect Dis 2004;38:649-54.
83. Otero L, Alcalá B, Varela JA, Miguel MD, Vázquez JA, Vázquez F. First isolate of a Neisseria gonorrhoeae strain associated with an ofloxacin treatment failure in Spain: case report. Sex Transm Dis 2001;28:576-8.
84. Alcalá B, Arreaza L, Salcedo C, Antolin I, Borrell N, Cacho J, et al. Molecular characterization of ciprofloxacin resistance of gonococcal strains in Spain. Sex Transm Dis 2003;30:395-8.
85. Otero L, Villar H, Vázquez JA, Vázquez F. Neisseria gonorrhoeae resistente a quinolonas: un nuevo problema de salud pública en España. Enferm Infecc Microbiol Clin 2002;20:123-6.
86. Arreaza L, Salcedo C, Alcalá B, Berron S, Martín E, Vázquez JA. Antibiotic resistance of Neisseria gonorrhoeae in Spain: trends over the last two decades. J Antimicrob Chemother 2003;51:153-6.
87. Schwebke JR, Whittington W, Rice RJ, Handsfield HH, Hale J, Holmes KK. Trends in susceptibility of Neisseria gonorrhoeae to ceftriaxone from 1985 through 1991. Antimicrob Agents Chemother 1995;39:917-20.
88. Wang SA, Lee MV, O'Connor N, Iverson CJ, Ohye RG, Whiticar PM, et al. Multidrug-resitant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin Infect Dis 2003;37:849-52.
89. Anónimo. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2001. World Health Organization. Commun Dis Intell 2002;26:541-5.
90. Boslego JW, Tramont EC, Takafuji ET, Diniega BM, Mitchell BS, Small JW, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987;317:272-8.
91. Surveillance of antibiotic susceptibility of Neisseria gonorrhoeae in the WHO western Pacific region 1992-4. WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme. Genitourin Med 1997;73:355-61.
92. Arreaza L, Vázquez F, Alcalá B, Otero L, Salcedo C, Vázquez JA. Emergence of gonococcal strains with resistance to azithromycin in Spain. J Antimicrob Chemother 2003;51:190-1.
93. Taylor-Robinson D. Mycoplasma genitalium - an update. Int J STD AIDS 2002;13:145-51.
94. Totten PA, Schwartz MA, Sjostrom KE, Kenny GE, Handsfield HH, Weiss JB, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001;183:269-76. (Erratum in: J Infect Dis 2003;187:1506).
95. Totten PA, Schwartz MA, Sjostrom KE, Kenny GE, Handsfield HH, Weiss JB, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001;183:269-76. (Erratum in: J Infect Dis 2003;187:1506).
96. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 543.
97. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 590.
98. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 732.
99. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 733.
100. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 227.
101. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 86.
102. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 420.
103. Dutro SM, Hebb JK, Garin CA, Hughes JP, Kenny GE, Totten PA. Development and performance of a microwell-plate-based polymerase chain reaction assay for Mycoplasma genitalium. Sex Transm Dis 2003;30:756-63.
104. Yoshida T, Maeda S, Deguchi T, Miyazawa T, Ishiko H. Rapid detection of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum, and Ureaplasma urealyticum organisms in genitourinary samples by PCR-microtiter plate hybridization assay. J Clin Microbiol 2003;41:1850-5.
105. Ren Y, Zhu X. Investigation on biovars and genotypes of Ureaplasma urealyticum in the cervix in a Chinese gynecologic check-up population and sex workers. Acta Derm Venereol 2003;83:175-8.
106. Robertson JA, Stemke GW, Davis JW Jr, Harasawa R, Thirkell D, Kong F, et al. Proposal of Ureaplasma parvum sp. nov. and emended description of Ureaplasma urealyticum (Shepard et al, 1974) (Robertson et al, 2001). Int J Syst Evol Microbiol 2002;52:587-97.
107. Naessens A, Foulon W, Breynaert J, Lauwers S. Serotypes of Ureaplasma urealyticum isolated from normal pregnant women and patients with pregnancy complications. J Clin Microbiol 1988;26:319-22.
108. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines. Antimicrob Agents Chemother 1994;38:2628-32.
109. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996;40:1048-9.
110. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001;45:2604-8.
111. Deguchi T, Maeda S, Tamaki M, Yoshida T, Ishiko H, Ito M, et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother 2001;48:742-4.
112. th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 388.
113. Alexel K. Mycoplasma genitalium: optimal method of treatment. Program and abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research; July 27-30, 2003; Ottawa, Ontario, Canada. Abstract 616.
114. Orle KA, Gates CA, Martín DH, Body BA, Weiss JB. Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex viruses types-1 and -2 from genital ulcers. J Clin Microbiol 1996;34:49-54.
115. Greenblatt RM, Lukehart SA, Plummer FA, Quinn TC, Critchlow CW, Ashley RL, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988;2:47-50.
116. Simonsen JN, Cameron DW, Gakinya MN, Ndinya-Achola JO, D'Costa LJ, Karasira P, et al. Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med 1988;319:274-8.
117. Parsons LM, Shayegani M, Waring AL, Bopp LH. DNA probes for the identification of Haemophilus ducreyi. J Clin Microbiol 1989;27:1441-5.
118. Gu XX, Rossau R, Jannes G, Ballard R, Laga M, Van Dyck E. The rrs(16S)-rrl(23S) ribosomal intergenic spacer region as a target for the detection of Haemoplilus ducreyi by a heminested PCR assay. Microbiology 1998;144:1013-9.
119. Parsons LM, Waring AL, Otido J, Shayegani M. Laboratory diagnosis of chancroid using species-specific primers from Haemophilus ducreyi groEL and the polymerase chain reaction. Diagn Microbiol Infect Dis 1995;23:89-98.
120. Johnson SR, Martin DH, Cammarata C, Morse SA. Alterations in sample preparation increase sensitivity of PCR assay for diagnosis of chancroid. J Clin Microbiol 1995;33:1036-8.
121. Flood JM, Sarafian SK, Bolan GA, Lammel C, Engelman J, Greenblatt RM, et al. Multistrain outbreak of chancroid in San Francisco, 1989-1991. J Infect Dis 1993;167:1106-11.
122. Sarafian SK, Woods TC, Knapp JS, Swaminathan B, Morse SA. Molecular characterization of Haemophilus ducreyi by ribosomial DNA fingerprint. J Clin Microbiol 1991;29:1949-54.
123. Brown TJ, Ison CA. Non-radioactive ribotyping of Haemophilus ducreyi using a digoxigenin labelled cDNA probe. Epidemiol Infect 1993;110:289-95.
124. Pillay A, Hoosen AA, Kiepiela P, Sturm AW. Ribosomal DNA typing of Haemophilus ducreyi strains: proposal for a novel typing scheme. J Clin Microbiol 1996;34:2613-5.
125. Van Dyck E, Bogaerts J, Smet H, Tello WM, Mukantabana V, Piot P. Emergence of Haemophilus ducreyi resistance to trimethoprim-sulfamethoxazole in Rwanda. Antimicrob Agents Chemother 1994;38:1647-8.
126. Malonza IM, Tyndall MW, Ndinya-Achola JO, Maclean I, Omar S, MacDonald KS, et al. A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. J Infect Dis 1999;180:1886-93.
127. Lewis DA. Chancroid: from clinical practice to basic science. AIDS Patient care STDs 2000;14:19-36.
128. Sng EH, Lim AL, Rajan VS, Goh AJ. Characteristics of Haemophilus ducreyi. A study. Br J Vener Dis 1982;58:239-42.
129. Knapp JS, Back AF, Babst AF, Taylor D, Rice RJ. In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid. Antimicrob Agents Chemother 1993;37:1552-5.
130. Tyndall M, Malisa M, Plummer FA, Ombetti J, Ndinya-Achola JO, Ronald AR. Ceftriaxone no longer predictably cures chancroid in Kenya. J Infect Dis 1993;167:469-71.
131. Dangor Y, Ballard RC, Miller SD, Koornhof HJ. Treatment of chancroid. Antimicrob Agents Chemother 1990;34:1308-11.
132. Lewis DA. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect 2003;79:68-71.
133. Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev 1995;8:1-21.
134. Young H. Guidelines for serological testing for syphilis. Sex Transm Infect 2000;76:403-5.
135. Ooi C, Robertson P, Donovan B. Investigation of isolated positive syphilis enzyme immunoassay (ICE Murex) results. Int J STD AIDS 2002;13:761-4.
136. Bowden FJ, Bastian I, Johnston F. A community-based approach to the control of sexually transmitted diseases in the Northen Territory. Aust N JJ Public Health 1997;21:519-23.
137. Mertz KJ, Weiss JB, Webb RM, Levine WC, Lewis JS, Orle KA, et al. An investigation of genital ulcers in Jackson, Missisippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis 1998;178:1060-6.
138. Risbud A, Chan-Tack K, Gadkari D, Gangakhedkar RR, Shepherd ME, Bollinger R, et al. The etiology of genital ulcer disease by disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted clinics in Pune, India. Sex Transm Dis 1999;26:55-62.
139. Mertz KJ, Trees D, Levine WC, Lewis JS, Litchfield B, Pettus KS, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. J Infect Dis 1998;178:1795-8.
140. Morse SA. New tests for bacterial sexually transmitted diseases. Curr Opin Infect Dis 2001;14:45-51.
141. Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, et al. Comparison of clinical and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997;175:583-9.
142. Zoechling N, Schluepen EM, Soyer HP, Kerl H, Volkenandt M. Molecular detection of Treponema pallidum in secondary and tertiary syphilis. Br J Dermatol 1997;136:683-6.
143. Horowitz HW, Valsamis MP, Wicher V, Abbruscato F, Larsen SA, Wormser GP, et al. Cerebral syphilitic gumma confirmed by the polymerase chain reaction in man with human immunodeficiency virus infection. N Engl J Med 1994;331:1488-91.
144. Hay PE, Clarke JR, Strugnell RA, Taylor-Robinson D, Goldmeier D. Use of the polymerase chain reaction to detect DNA sequences specific to pathogenic treponemes in cerebrospinal fluid. FEMS Microbiol Lett 1990;68:233-8.
145. Sánchez PJ, Wendel GD Jr, Grimprel E, Goldberg M, Hall M, Arencibia-Mireles O, et al. Evaluation of molecular methodologies and rabbit infectivity testing for the diagnosis of congenital syphilis and neonatal central nervous system invasion by Treponema pallidum. J Infect Dis 1993;167:148-57.
146. Centurion-Lara A, Castro C, Shaffer JM, Van Voorhis WC, Marra CM, Lukehart SA. Detection of Treponema pallidum by a sensitive reverse transcriptase PCR. J Clin Microbiol 1997;35:1348-52.
147. Ebel A, Vanneste L, Cardinaels M, Sablon E, Samson I, De Bosschere K, et al. Validation of the INNO-LIA syphilis kit as a confirmatory assay for Treponema pallidum antibodies. J Clin Microbiol 2000;38:215-9.
148. Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, et al. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2000;62:301-9.
149. Pietravalle M, Pimpinelli F, Maini A, Capoluongo E, Felici C, D'Auria L, et al. Diagnostic relevant of polymerase chain reaction technology for Treponema pallidum in subjects in differents phases of infection. Microbiologica 1999;22:99-104.
150. Van Voorhis WC, Barrett LK, Lukehart SA, Schmidt B, Schriefer M, Cameron CE. Serodiagnosis of syphilis: antibodies to recombinant Tp0453, Tp92, and Gpd proteins are sensitive and specific indicators of infection by Treponema pallidum. J Clin Microbiol 2003;41:3668-74.
151. Singh AE, Romanowski B. Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev 1999;12:187-209.
152. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chin M, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997;337:307-14.
153. Pillay A, Liu H, Chen CY, Holloway B, Sturm AW, Steiner B, et al. Molecular subtyping of Treponema pallidum subspecies pallidum. Sex Transm Dis 1998;25:408-14.
154. Schofer H, Vogt HJ, Milbradt R. Ceftriaxone for the treatment of primary and secondary syphilis. Chemotherapy 1989;35:140-5.
155. Moorthy TT, Lee CT, Lim KB, Tan T. Ceftriaxone for treatment of primary syphilis in men: a preliminary study. Sex Transm Dis 1987;14:116-8.
156. Hook EW 3rd, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002;29:486-90.
157. Marra CM, Boutin P, McArthur JC, Hurwitz S, Simpson PA, Haslett JA, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000;30:540-4.
158. Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex
159. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
160. Vanderhooft S, Kirby P. Genital herpes simplex infection. Natural history. Sem Dermatol 1992;11:190-9.
161. García-Corbeira P, Dal-Ré R, Aguilar L, Granizo JJ, García de Lomas J. Is sexual transmisión an important pattern for herpes simples type 2 virus seroconversion in the Spanish general population? J Med Virol 1999;59:194-7.
162. Varela JA, García-Corbeira P, Aguanell MV, Boceta R, Ballesteros J, Aguilar L, et al. Herpes simplex virus type 2 seroepidemiology in Spain. Sex Transm Dis 2001;28:47-50.
163. Roberts CM, Pfister JR, Apear SJ. Increasing porportion of herpes simples infection in collage students. Sex Transm Dis 2003;30:797-800.
164. Sanra Z, Scherf E, Dan M. Herpes simples virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel. Sex Transm Dis 2003;30:794-6.
165. Nilsen A, Myrmel H. Changing trends in herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand 2000;79:693-6.
166. Mertz GJ, Rosenthal SL, Stranberry LR. Is Herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episode of genital herpes? Sex Transm Dis 2003;30:801-2.
167. Slomka MJ, Emery L, Munday PE, Moulsdale M, Brown DW. A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. J Med Virol 1998;55:177-83.
168. Cullen AP, Long CD, Lorincz AT. Rapid detection and typing of herpes simplex virus DNA in clinical specimens by the Hybrid Capture III signal amplification probe test. J Clin Microbiol 1997;35:2275-8.
169. Díaz-Mitoma F, Ruben M, Sacks S, MacPherson P, Caissie G. Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes. J Clin Microbiol 1996;34:657-63.
170. Hobson A, Wald A, Wright N, Corey L. Evaluation of a quantitative competitive PCR assay for measuring herpes simples virus DNA content in genital tract secretions. J Clin Microbiol 1997;35:548-52.
171. Scoular A, Gillespie G, Carman WF. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect 2002;78:21-5.
172. Koenig M, Reynolds KS, Aldous W, Hickman M. Comparison of Light-Cycler PCR, enzyme immunoassay, and tissue culture for detection of herpes simplex virus. Diagn Microbiol Infect Dis 2001;40:107-10.
173. Ndjoyi-Mbiguino A, Ozouaki F, Legoff J, Mbopi-Keou FX, Si-Mohamed A, Onas IN, et al. Comparison of washing and swabbing procedures for collecting genital fluids to assess cervicovaginal shedding of herpes simplex virus type 2 DNA. J Clin Microbiol 2003;41:2662-4.
174. Morrow RA, Friedrich D, Krantz E. Performance of the focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes. J Clin Microbiol 2003;41:5212-4.
175. Morrow RA, Friedrich D. Inaccuracy of certain commercial enzyme immunoassays in diagnosing genital infections with herpes simplex virus types 1 or 2. Am J Clin Pathol 2003;120:839-44.
176. Page J, Taylor J, Tideman RL, Seifert C, Marks C, Cunningham A, et al. Is HSV serology useful for the management of first episode genital herpes? Sex Transm Infect 2003;79:276-9.
177. Cherpes TL, Meyn LA, Hillier SL. Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay. J Clin Microbiol 2003;41:2758-9.
178. Ashley RL, Wald A. Genital herpes: Review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999;12:1-8.
179. Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992;327:782-9.
180. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
181. Reyes M, Shaik NS, Graber JM, Nisenbaum R, Wetherall NT, Fukuda K, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003;163:76-80.
182. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 2000;355:1981-7.
183. Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, Paranjape RS, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003;187:1513-21.
184. Crumpacker CS. Use of antiviral drugs to prevent herpesvirus transmission. N Engl J Med 2004;350:67-8.
185. Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998;42:868-72.
186. Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr 1992;5(Suppl 1):S29-32.
187. Barton SE, Munday PE, Kinghorn GR, Van der Meijden WI, Stolz E, Notowicz A, et al. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. Genitourin Med 1986;62:247-50.
188. Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193-6.
189. Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994;18:570-8.
190. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. Drugs 2000;60:1329-52.
191. Flamel Technologies. Viropump investigator's brochure. Vénissieux: Flamel Technologies, 1998.
192. Morrison LA. Vaccines against genital herpes: progress and limitations. Drugs 2002;62:1119-29.
193. Goldberg J. Studies on granuloma inguinale. V. Isolation of a bacterium resembling Donovania granulomatis from the feces of a patient with granuloma inguinale. Br J Vener Dis 1962;38:99.
194. Mittal A, Chandra M. In vitro cultivation of Calymmatobacterium granulomatis in cultured macrophages. Indian J Sex Transm Dis 1992;13:68.
195. Kharsany AB, Hoosen AA, Kiepiela P, Naicker T, Sturm AW. Culture of Calymmatobacterium granulomatis. Clin Infect Dis 1996;22:391.
196. Kharsany AB, Hoosen AA, Kiepiela P, Naicker T, Sturm AW. Growth and cultural characteristics of Calymmatobacterium granulomatis-the aetiological agent of granuloma inguinale (Donovanosis). J Med Microbiol 1997;46:579-85.
197. Carter J, Bowden FJ, Sriprakash KS, Bastian I, Kemp DJ. Diagnostic polymerase chain reaction for donovanosis. Clin Infect Dis 1999;28:1168-9.
198. Carter JS, Bowden FJ, Bastian I, Myers GM, Sriprakash KS, Kemp DJ. Phylogenetic evidence for reclassification of Calymmatobacterium granulomatis as Klebsiella granulomatis comb. nov. Int J Syst Bacteriol 1999;49:1695-700.
199. Kharsany AB, Hoosen AA, Kiepiela P, Kirby R, Sturm AW. Phylogenetic analysis of Calymmatobacterium granulomatis based on 16S rRNA gene sequences. J Med Microbiol 1999;48:841-7.
200. Bastian I, Borden FJ. Amplification of Klebsiella-like sequences from biopsy specimens from patients with donovanosis. Clin Infect Dis 1996;23:1328.
201. Bosch FX, De Sanjosé S, Lloveras B. La endemia oculta de las infecciones por el virus del papiloma humano: Características y riesgos. En: Palacio V, editor. La infección VPH en el área genital: clínica, diagnóstico y tratamiento. Madrid: 3M, 2000; p. 37-45.
202. De Sanjosé S, Almirall R, Lloveras B, Font R, Díaz M, Muñoz N, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-93.
203. Canadas MP, Bosch FX, Junquera ML, Ejarque M, Font R, Ordóñez E, et al. Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol 2004;42:1330-2.
204. Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuosly high sexual acivity. Sex Transm Dis 2000;27:438-45.
205. Touzé A, De Sanjosé S, Coursaget P, Almirall MR, Palacio V, Meijer CJ, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the genital population and in prostitutes. J Clin Microbiol 2001;39:4344-8.
206. Van der Snoek EM, Niesters HG, Mulder PG, Van Doornum GJ, Osterhaus AD, Van der Meijden WI. Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study. Sex Transm Dis 2003;30:639-44.
207. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
208. Low SH, Thong TW, Ho TH, Lee YS, Morita T, Singh M, et al. Prevalence of human papillomavirus types 16 and 18 in cervical carcinomas: a study by dot and Southern blot hybridization and the polymerase chain reaction. Jpn J Cancer Res 1990;81:1118-23.
209. Jacobs MV, De Roda Husman AM, Van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995;33:901-5.
210. Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996;34:745-7.
211. De Roda Husman AM, Walboomers JM, Van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76:1057-62.
212. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170:1077-85.
213. Kleter B, Van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, Ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
214. Finan RR, Irani-Hakime N, Tamin H, Almawi WY. Validity of vaginal testing in detecting human papillomavirus (HPV) genotypes. J Clin Virol 2000;19:163-8.
215. Shah KV, Daniel RW, Tennant MK, Shah N, McKee KT Jr, Gaydos CA, et al. Diagnosis of human papillomavirus infection by dry vaginal swabs in military women. Sex Transm Infect 2001;77:260-4.
216. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998;134:25-30.
217. Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol 2000;43 (1 Pt 2):S12-7.
218. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-8.
219. Steller MA. Cervical cancer vaccines: progress and prospects. J Soc Gynecol Investig 2002;9:254-64.
220. Murakami M, Gurski KJ, Steller MA. Human papillomavirus vaccines for cervical cancer. J Immunother 1999;22:212-8.
221. Van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, Van Rossum AB, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999;35:946-52.
222. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29:725-35.
223. Becker TM, Blount JH, Douglas J, Judson FN. Trends in Molluscum contagiosum in the United States, 1966-1983. Sex Transm Dis 1986;13:88-92.
224. Liota E, Smith KJ, Buckley R, Menon P, Skelton H. Imiquimod therapy for Molluscum contagiosum. J Cutan Med Surg 2000;4:76-82.
225. Tyring SK. Molluscum contagiosum: the importance of early diagnosis and treatment. Am J Obstet Gynecol 2003;189(3 Suppl):S12-6.
226. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003;36:663-8.
227. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003;189:139-47.
228. Leitich H, Brunbauer M, Bodner-Adler B, Kaider A, Egarter C, Husslein P. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol. 2003;188:752-8.
229. Guise JM, Mahon SM, Aickin M, Helfand M, Peipert JF, Westhoff C. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001;20(Suppl):62-72.
230. McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2003;(2):CD000262.
231. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol 1990;75:52-8.
232. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiological associations. Am J Med 1983;74:14-22.
233. Nugent PP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standarized method of Gram stain interpretation. J Clin Microbiol 1991;29:297-301.
234. Myziuk L, Romanowski B, Jonson SC. BVBlue test for diagnosis of bacterial vaginosis. J Clin Microbiol 2003;41:1925-8.
235. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 2004;80:8-11.
236. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999;28(Suppl 1):S57-S65.
237. Boris S, Barbés C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2000;2:543-6.
238. Boris S, Suárez JE, Vázquez F, Barbes C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Infect Immun 1998;66:1985-9.
239. Andersch B, Linden D, Dahlen I, Brandberg A. Bacterial vaginosis and the effect of intermittent prophylactic treatment with an acid lactate gel. Gynecol Obstet Invest 1990;30:114-9.
240. Andreeva P, Slavchev B, Kovachev S, Nacheva A, Vacheva R. Treatment of bacterial vaginosis with high dosage metronidazole and lactic acid. Akusherstvo i ginekologiia 2002;41:36-9.
241. Milani M, Barcellona E, Agnello A. Efficacy of the combination of 2 grm oral tinidazole ad acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial. Eur J Obstet Gynecol Reprod Biol 2003;109:67-71.
242. García Figueroa RG, Sauceda L, Ramírez Palacios D, Cruz Talonia F, Romero Cabello R. Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis Ginecol Obstet Mex 2000;68:154-9.
243. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2001; (4):CD002845.
244. Otero L, Vázquez F, Palacio V, Vázquez S, Carreno F, Méndez FJ. Comparison of seven phenotyping methods for Candida albicans. Eur J Epidemiol 1995;11:221-4.
245. Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001;185:363-9.
246. Sobel JD, Vázquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996;22:726-7.
247. Babula O, Lazdane G, Kroica J, Ledger NJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding gene polymorphism in Latvian women. Clin Infect Dis 2003;37:733-7.
248. Mardh P-A, Novikova N, Stukalova E. Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candiosis. Intern J Obstet & Gynecol 2003;110:934-7.
249. Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997;176:138-41.
250. Otero L, Palacio V, Carreno F, Méndez FJ, Vázquez F. Vulvovaginal candidiasis in female sex workers. Int J STD AIDS 1998;9:526-30.
251. Otero L, Fleites A, Méndez FJ, Palacio V, Vázquez F. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to anti-fungal agents and boric acid. Eur J Clin Microbiol Infect Dis 1999;18:59-61.
252. Otero L, Palacio V, Méndez FJ, Vázquez F. Boric acid susceptibility testing of non-C. albicans Candida and Saccharomyces cerevisiae: comparison of three methods. Med Mycol 2002;40:319-22.
253. Hilton E, Rindos P, Isenberg HD. Lactobacillus GG vaginal suppositories and vaginitis. J Clin Microbiol 1995;33:1433.
254. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992;116:353-7.
255. Jackson DJ, Rakwar JP, Bwayo JJ, Kreiss JK, Moses S. Urethral Trichomonas vaginalis infection and HIV-1 transmission [letter]. Lancet 1997;350:1076.
256. Hobbs MM, Kazembe P, Reed AW, Miller WC, Nkata E, Zimba D, et al. Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 1999;26:381-7.
257. Lefevre JC, Lepargneur JP, Bauriaud R, Bertrand MA, Blanc C. Clinical and microbiologic features of urethritis in men in Toulouse, France. Sex Transm Dis 1991;18:76-9.
258. Janier M, Lassau F, Casin I, Grillot P, Scieux C, Zavaro A, et al. Male urethritis with and without discharge: A clinical and microbiological study. Sex Transm Dis 1995;22:244-52.
259. Krieger JN, Alderete JF. Trichomonas vaginalis and trichomoniasis. En: Holmes KK, Sparling PF, Mardh P-A, et al, editors. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999; p. 587-604.
260. Miller GA, Klausner JD, Coates TJ, Meza R, Gaydos CA, Hardick J, et al. Assessment of a rapid antigen detection system for Trichomonas vaginalis infection. Clin Diagn Lab Immunol 2003;10:1157-8.
261. Krieger JN, Tam MR, Stevens CE, Nielsen IO, Hale J, Kiviat NB, et al. Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA 1988;259:1223-7.
262. Smith RF. Detection of Trichomonas vaginalis in vaginal specimens by direct immunofluorescence assay. J Clin Microbiol 1986;24:1107-8.
263. Yule A, Gellan MCA, Oriel JD, Packers J. Detection of Trichomonas vaginalis antigen in women by enzyme immunoassay 1987;40:566-8.
264. Briselden AM, Hillier SL. Evaluation of Affirm VP microbial identification test for Gardnerella vaginalis and Trichomonas vaginalis. J Clin Microbiol 1994;32:148-52.
265. Judson FN, Ehret J. Laboratory diagnosis of sexually transmitted infections. Pediatr Ann 1994;23:361-9.
266. Ordás J, Pérez F, Villar M, Melón S, Morilla A, Méndez FJ, et al. Diagnóstico de tricomoniasis mediante PCR. Program y resúmenes del XI Congreso Nacional de la SEIMC, 16-19 de mayo de 2004, Bilbao [en prensa].
267. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998;11:300-17.
268. Vázquez F, Palacio V, Ramos I, Bello MF, Llaneza J. Evaluación de un método de inmunofluorescencia mediante anticuerpos monoclonales para el diagnóstico de Trichomonas vaginalis (Abstract). VIII Congreso Nacional del Grupo Español para la Investigación de las ETS, Vigo, 1990.
269. Witkin SS, Inglis SR, Polaneczky M. Detection of Chlamydia trachomatis and Trichomonas vaginalis by polymerase chain reaction in introital specimen from pregnant women. Am J Obstet Gynecol 1996;175:165-7.
270. Heine RP, Wiesenfeld HC, Sweet RL, Witkin SS. Polymerase chain reaction analysis of distal vaginal specimens: a less invasive strategy for detection of Trichomonas vaginalis. Clin Infect Dis 1997;24:985-7.
271. DeMeo LR, Draper DL, McGregor JA, Moore DF, Peter CR, Kapernick PS, et al. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol 1996;174:1339-42.
272. Madico G, Quinn TC, Rompalo A, McKee KT Jr, Gaydos CA. Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab simples. J Clin Microbiol 1998;36:3205-10.
273. Paterson BA, Tabrizi SN, Garland SM, Fairley CK, Bowden FJ. The tampon test for trichomoniasis: a comparison between conventional methods and a polymerase chain reaction for Trichomonas vaginalis in women. Sex Tranms Infect 1998;74:136-9.
274. Lin RR, Shaio ME, Liu JY. One-tube, nested-PCR assay for the detection of Trichomonas vaginalis in vaginal discharges. Ann Trop Med Parasitol 1997;91:61-5.
275. Hardick J, Yang S, Lin S, Duncan D, Gaydos C. Use of the Roche Light Cycler instrument in a real-time PCR for Trichomonas vaginalis in urine samples from females and males. J Clin Microbiol 2003;41:5619-22.
276. Crucitti T, Van Dyck E, Tehe A, Abdellati S, Vuylsteke B, Buve A, et al. Comparison of culture and different PCR assays for detection of Trichomonas vaginalis in self collected vaginal swab specimens. Sex Transm Infect 2003;79:393-8.
277. Vázquez F, García MJ, Pérez F, Palacio V. Trichomonas vaginalis: tratamiento y resistencia a nitroimidazoles. Enferm Infecc Microbiol Clin 2001;19:114-24.
278. Meri T, Jokiranta TS, Suhonen L, Meri S. Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol 2000;38:763-7.
279. Lossick JG. Therapy of urogenital trichomoniasis. En: Honigberg BM, editor. Trichomonads Parasitic in Humans. New York: Springer Verlag, 1989; p. 326-41.
280. Pérez S, Fernández-Verdugo A, Pérez F, Vázquez F. Prevalence of 5-nitroimidazole-resistant Trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis 2001;28:115-6.
281. Varela JA, Otero L, Espinosa E, Sánchez C, Junquera ML, Vázquez F. Phthirus pubis in a sexually transmitted diseases unit: a study of 14 years. Sex Transm Dis 2003;30:292-6.
282. Chapel TA, Katta T, Kuszmar T, DeGiusti D. Pediculosis pubis in a clinic for treatment of sexually transmitted diseases. Sex Transm Dis 1979;6:257-60.
283. Witkowski JA, Parish LC. Pediculosis and resistance: the perennial problem. Clin Dermatol 2002;20:87-92.
284. Purvis RS, Tyring SK. An outbreak of lindane-resistant scabies treated successfully with permethrin 5% cream. J Am Acad Dermatol 1991;25:1015-6.
285. Roth WI. Scabies resistant to lindane 1% lotion and crotamiton 10% cream. J Am Academ Dermatol 1991;24:502-3.
286. Otero L, Vázquez F. Nuevos patógenos genitales. Enf Trans Sex 1993;7:171-5.
287. Vázquez F, Andrés MT, Palacio V, Vázquez S, De Lillo A, Fierro JF. Aislamiento de Haemophilus influenzae y Haemophilus parainfluenzae en infecciones genitourinarias: una revisión de 4 años. Enferm Infecc Microbiol Clin 1996;14:181-5.
288. Cox RA, Slack MP. Clinical and microbiological features of Haemophilus influenzae vulvovaginitis in young girls. J Clin Pathol 2002;55:961-4.
289. Otero L, Blanco MI, De la Iglesia P, Viejo G, Miguel D, Del Valle A, et al. Aislamiento de Neisseria meningitidis maltosa negativa en exudado vaginal. Enferm Infecc Microbiol Clin 2002;20:238-9.
290. McKenna JG, Fallon RJ, Moyes A, Young H. Anogenital non-gonococcal Neisseriae: prevalence and clinical significance. Int J STD AIDS 1993;4:8-12.
291. Carpenter CM, Charles R. Isolation of meningococcus from the genitourinary tract of seven patients. Am J Public Health 1942;32:640-3.
292. Karolus JJ, Gandelman AL, Nolan BA. Urethritis caused by Neisseria meningitidis. J Clin Microbiol 1980;22:284-5.
293. Harriau P, Ramanantsoa C, Pierre F, Riou JY, Quentin R. Endocervical infection in a pregnant woman caused by Neisseria meningitidis: evidence of associated oropharyngeal colonization of the male partner. Eur J Obstet Gynecol Reprod Biol 1997;74:145-7.
294. Barnes RC, Daifuku R, Roddy RE, Stamm WE. Urinary-tract infection in sexually active homosexual men. Lancet 1986;1(8474):171-3.
295. Reina J, Gil J, Salva F, Gómez J, Alomar P. Microbiological characteristics of Weeksella virosa (formerly CDC group IIf) isolated from the human genitourinary tract. J Clin Microbiol 1990;28:2357-9.
296. Otero L, Palacio V, Vázquez F. Tinea cruris in female prostitutes. Mycopathologia 2002;153:29-31.
297. Richens J. Genital manifestations of tropical diseases. Sex Transm Infect 2004;80:12-7.